Oct 2024 $10 M Private placement after listing $10 to $50 million 9
Coya Therapeutics, Inc.: Private sale, Oct 2024 × Investors in this round 9 investors had bought by the notice of Oct 28, 2024: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice David Snyder · Executive Officer Fred Grossman · Executive Officer Howard Berman · Executive Officer, Director Anabella Villalobos · Director Ann Lee · Director Arun Swaminathan · Director Dieter Weinand · Director Dov Goldstein · Director Hideki Garren · Director Wilbur Ross · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Wilmington Capital Securities, LLC (CRD 000133839) · Garden City,, New York Sold in all US states Chardan Capital Markets LLC (CRD 000120128) · New York, New York Sold in all US states BTIG, LLC (CRD 000122225) · San Francisco, California Sold in all US states Remarks in the notice On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”Signed by Howard Berman, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 28, 2024. Read the notice at the SEC .
equity SEC Dec 2023 $26 M Private placement after listing $10 to $50 million 122
Coya Therapeutics, Inc.: Private sale, Dec 2023 × Investors in this round 122 investors had bought by the notice of Dec 20, 2023: 122 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $26 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice David Snyder · Executive Officer Fred Grossman · Executive Officer Howard Berman · Executive Officer, Director Anabella Villalobos · Director Ann Lee · Director Dieter Weinand · Director Dov Goldstein · Director Hideki Garren · Director Wilbur Ross · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round BTIG, LLC (CRD 122225) · San Francisco, California Sold in all US states Newbridge Securities Corporation (CRD 104065) · Boca Raton, Florida Sold in all US states Remarks in the notice On fees: “The Company paid BTIG and Newbridge a fee based on gross proceeds from the sale of securities placed by each placement agent respectively and issued to Newbridge a warrant exercisable for 196,168 shares of Common Stock.”On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”Signed by Howard Berman, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2023. Read the notice at the SEC .
equity, options SEC Apr 2022 $10 M No. 2 $10 to $50 million 45
Coya Therapeutics, Inc.: Raise no. 2, Apr 2022 × Investors in this round 45 investors had bought by the notice of May 20, 2022: 45 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $20 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,400,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Adrian Hepner · Executive Officer David Snyder · Executive Officer Greg MacMichael · Executive Officer Howard Berman · Executive Officer, Director Anabella Villalobos · Director Ann Lee · Director Dov Goldstein · Director Hideki Garren · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Wilmington Capital Securities, LLC (CRD 133839) · Garden City, New York Sold in AL, AZ, CA, CO, CT, FL, GA, IL, IN, MA, MD, MI, MN, MO, NC, NH, NV, OH, PA, TN, TX, VA, WV, and outside the US Remarks in the notice On fees: “Assumes maximum commissions earned. Excludes value of warrants to purchase shares of common stock in an amount equal to 7% of the aggregate number of shares of equity securities ultimately issued upon conversion of the notes.”On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3”Signed by Howard Berman, Ceo. Source: SEC Form D, newest notice filed May 20, 2022. Read the notice at the SEC .
debt, options SEC Dec 2020 $10 M No. 1 $10 to $50 million 57
Coya Therapeutics, Inc.: Raise no. 1, Dec 2020 × Investors in this round 57 investors had bought by the notice of Jan 5, 2021: 57 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Andrea Goldstein · Executive Officer, Director Howard Berman · Executive Officer, Director Jani Tuomi · Director Shawn M. Titcomb · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Tribal Capital Markets, LLC (CRD 38901) · broker-dealer Shawn M. Titcomb (CRD 2596352) · Sarasota, Florida Sold in AL, AZ, CA, FL, IL, KY, MD, MI, NJ, NY, OH, TX, and outside the US Remarks in the notice On fees: “In addition to the sales commissions, a warrant to purchase 525,049 shares of the issuer's common stock at a price per share of $1.606 was issued.”Signed by Frances Dea, Attorney-in-Fact. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC .
equity, options SEC